PharmaNest to Present Seven Digital Pathology and AI Communications and Abstracts at the International Liver Congress — EASL 2024, Including Analytical and Clinical Validation
PharmaNest, a leader in high-resolution, single-fiber quantitative Digital Pathology and Artificial Intelligence, showcases the performance of its FibroNest Ph-FCS digital biomarker for quantifying fibrosis severity...
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and...
Ground-Breaking Human Trial by Temple Therapeutics Solves 187-Year-Old Surgical Mystery of Eradicating Painful Adhesions
Rope-like bands of internal scar tissue that form in 70-90% of patients who undergo abdominal surgery have bedeviled patients and surgeons since medical literature history's...
BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim – a New Model for Building an External Innovation Ecosystem on an Industry Campus
BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs. The...
Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE’s. Will Engage FDA for Clearance of the P2a PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderate/severe ARDS subjects.Expected screening for enrolled subjects to begin April/May...